Abstract 1444P
Background
In the United States, uniquely American risk factors have led to a rise in the incidence of esophageal adenocarcinoma. In contrast, Asians have generally shown a predominance of esophageal squamous cell carcinoma (SCC), and this has held among Asian-Americans. However, limited investigation of esophageal cancer within Asian-Americans has been conducted in recent years.
Methods
The Surveillance, Epidemiology, and End Results (SEER) Incidence Database was queried for patients from 2004-2020 classified as Asian/Pacific Islander and diagnosed with esophageal adenocarcinoma or squamous cell carcinoma. Descriptive statistics and multivariate models were utilized to compare incidence, cancer characteristics, treatment details, and survival in patients with esophageal adenocarcinoma and SCC.
Results
During this time, 2103 (73.71%) Asian-Americans presented with esophageal SCC compared to 750 (26.29%) with adenocarcinoma. Patients with SCC were diagnosed at a significantly older age (68.09 vs 66.10, p=<0.0001) and had a larger distribution of females (28.72% vs 15.20%, p<0.0001) than those with adenocarcinoma. The distribution of tumor stage was significantly different across these two groups (p<0.0001), with 292 (38.93%) adenocarcinoma patients diagnosed at stage IV compared to 546 (25.96%) patients with SCC. Cox regression analysis revealed that SCC was independently associated with worse survival (Hazard Ratio 1.115 (1.08-1.233)) compared to esophageal adenocarcinoma. Table: 1444P
Histological subtype | p-value | ||
Squamous cell carcinoma (N = 2103), N (%) | Adenocarcinoma (N = 750), N (%) | ||
Age, mean (years) | 68.09 | 66.10 | <0.0001 |
Sex | <0.0001 | ||
Female | 604 (28.72) | 114 (15.20) | |
Male | 1499 (71.28) | 636 (84.80) | |
Derived stage | <0.0001 | ||
I | 196 (9.32) | 72 (9.60) | |
II | 379 (18.02) | 97 (12.93) | |
III | 547 (26.01) | 166 (22.13) | |
IV | 546 (25.96) | 292 (38.93) | |
Unknown | 435 (20.68) | 123 (16.40) | |
Location of tumor | <0.0001 | ||
Upper third | 276 (13.12) | 11 (1.47) | |
Middle third | 692 (32.91) | 43 (5.73) | |
Lower third | 547 (26.01) | 566 (75.47) | |
Unclear/NOS | 588 (27.96) | 130 (17.33) | |
Cause of death | <0.0001 | ||
Alive | 452 (21.49) | 177 (23.6) | |
Esophageal cancer | 1300 (61.82) | 411 (54.8) | |
Other cause of death | 351 (16.69) | 162 (21.6) |
Conclusions
SCC remains the predominant histological subtype of esophageal cancer within Asian-Americans. Several factors may contribute to this, including BMI, immigration history, and retained cultural practices. However, adenocarcinoma should not be missed in this cohort. The later stage diagnosis of adenocarcinoma suggests that methods to improve early detection are necessary, and poorer survival of the SCC cohort indicates an opportunity to improve treatment paradigms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1927P - AL2846 in patients (pts) with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) previously treated with tyrosine kinase inhibitors (TKI): Preliminary clinical results from the phase Ib study
Presenter: Feng Shi
Session: Poster session 18
Resources:
Abstract
1928P - Camrelizumab plus apatinib mesylate in patients with recurrent or metastatic poorly differentiated thyroid carcinoma (PDTC) /anaplastic thyroid carcinoma (ATC): A prospective, open-label, phase II study
Presenter: Jun Cao
Session: Poster session 18
Resources:
Abstract
1929P - Dabrafenib and trametinib (D+T) in BRAFV600E differentiated thyroid cancer: A real-world experience in Italy
Presenter: Laura Locati
Session: Poster session 18
Resources:
Abstract
1930P - Resensitization of BRAF-mutated radioactive iodine refractory differentiated thyroid cancer with longer duration of dabrafenib and trametinib
Presenter: Jiaxin Niu
Session: Poster session 18
Resources:
Abstract
1931P - Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
Presenter: Winston Wong
Session: Poster session 18
Resources:
Abstract
1932P - Tyrosine kinase inhibitors-induced erythrocytosis in thyroid cancers: A novel safety signal from a retrospective study
Presenter: Silvia Marchesi
Session: Poster session 18
Resources:
Abstract
1933P - Utility of circulating tumoral DNA analysis by multi-gene NGS panels in tracking therapy progression of advanced sporadic medullary thyroid carcinoma
Presenter: Raffaele Ciampi
Session: Poster session 18
Resources:
Abstract
1934P - Active surveillance for higher-risk papillary thyroid carcinoma in China: A 10-year retrospective study
Presenter: Yan Hu
Session: Poster session 18
Resources:
Abstract
1935P - Sequence matters: Impact of first-line response in overall therapeutic outcome in differentiated thyroid cancer. Data from the Spanish national registry of thyroid cancer (REGETNE-Tiroides)
Presenter: Sergio Pérez Fernandez
Session: Poster session 18
Resources:
Abstract
1936P - Treatment outcomes of patients with anaplastic thyroid carcinoma (atc): Multicentric data from spanish national registry (regetne-tiroides)
Presenter: José Miguel Rodellar
Session: Poster session 18
Resources:
Abstract